OMOliver Donoso Mantke

Oliver Donoso Mantke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oliver Donoso Mantke has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnosis of West Nile Virus Human Infections: Overview and Proposal of Diagnostic Protocols Considering the Results of External Quality Assessment Studies

    by Vittorio Sambri, Maria R. Capobianchi, Francesca Cavrini, Rémi Charrel, Olivier Donoso-Mantke, Camille Escadafal, Leticia Franco, Paolo Gaibani, Ernest A. Gould, Matthias Niedrig, et al.

    West Nile virus, genus Flavivirus, is transmitted between birds and occasionally other animals by ornithophilic mosquitoes. This virus also infects humans causing asymptomatic infections in about 85% of cases and <1% of clinical cases progress to severe neuroinvasive disease. The virus also presents a threat since most infections remain unapparent. However, the virus contained in blood and organs from asymptomatically infected donors can be transmitted to recipients of these infectious tissues. This paper reviews the presently available methods to achieve the laboratory diagnosis of West Nile virus infections in humans, discussing the most prominent advantages and disadvantages of each in light of the results obtained during four different External Quality Assessment studies carried out by the European Network for ‘Imported’ Viral Diseases (ENIVD).


  • Open Access

    Tick-borne encephalitis in Europe, 2007 to 2009

    by O Donoso Mantke, C Escadafal, M Niedrig, M Pfeffer, collective on behalf of the Working group for

    As a follow-up of a retrospective survey on tick borne-encephalitis (TBE) in 2008, the European Network for Diagnostics of 'Imported' Viral Diseases launched a new survey in 2010, to collect broader information on TBE prevalence between 2007 and 2009 and to observe possible changes compared to the previous data. A two-part questionnaire was mailed to contact points in all European Union (EU) Member States and four non-EU countries (Bosnia and Herzegovina, Norway, Russia, and Switzerland). The first part was identical to the 2008 survey, requesting information on case definition, diagnostic methods, investigations regarding tick-transmitted diseases, endemic foci mapping, vaccination programmes, and recommendations for travellers. The second newly added part, inquired about geographic and seasonal distribution of TBE cases, imported cases, TBE subtypes, animal cases, and prevalence in ticks and wildlife hosts. Of 28 participat-ing countries, 16 had TBE as a notifiable disease, as in the first survey. In the 2007-2009 period, the total number of notified cases (17,818) was lower than in 2004-2006 (21,339 cases), also when subtracting Russian cases (8,207 vs 9,073 cases respectively). The highest reported incidence was 18.5 per 100,000 population in Lithuania in 2009. The 2010 study showed that increased numbers of countries used PCR and nucleotide sequencing for particular investigations. Most countries, however, relied on specific antibody detection by enzyme linked immunosorbent assay for TBE laboratory diagnosis. Disparities nevertheless remained across countries regarding case definitions, and surveillance and prevention activities. To understand changing patterns in TBE transmission, surveillance strategies including screening of vector ticks and testing of animal hosts should be harmonised and done more systematically in Europe. Collected data will support rec-ommendations concerning diagnostic and mapping methods, case reporting, vaccination programmes and information campaigns. .


  • Open Access

    2nd International External Quality Control Assessment for the Molecular Diagnosis of Dengue Infections

    by Cristina Domingo, Matthias Niedrig, Anette Teichmann, Marco Kaiser, Leonid Rumer, Richard G. Jarman, Oliver Donoso-Mantke

    Currently dengue viruses (DENV) pose an increasing threat to over 2.5 billion people in over 100 tropical and sub-tropical countries worldwide. International air travel is facilitating rapid global movement of DENV, increasing the risk of severe dengue epidemics by introducing different serotypes. Accurate diagnosis is critical for early initiation of preventive measures. Different reverse transcriptase PCR (RT-PCR) methods are available, which should be evaluated and standardized. Epidemiological and laboratory-based surveillance is required to monitor and guide dengue prevention and control programmes, i.e., by mosquito control or possible vaccination (as soon as an effective and safe vaccine becomes available). The purpose of the external quality assurance (EQA) study described is to assess the efficiency and accuracy of dengue molecular diagnosis methods applied by expert laboratories. A panel of 12 human plasma samples was distributed and tested for DENV-specific RNA. The panel comprised 9 samples spiked with different DENV serotypes (DENV-1 to DENV-4), including 10-fold dilution series of DENV-1 and DENV-3. Two specificity controls consisted of a sample with a pool of 4 other flaviviruses and a sample with chikungunya virus. A negative control sample was also included. Thirty-seven laboratories (from Europe, Middle East Asia, Asia, the Americas/Caribbean, and Africa) participated in this EQA study, and reports including 46 sets of results were returned. Performance among laboratories varied according to methodologies used. Only 5 (10.9%) data sets met all criteria with optimal performance, and 4 (8.7%) with acceptable performance, while 37 (80.4%) reported results showed the need for improvement regarding accomplishment of dengue molecular diagnosis. Failures were mainly due to lack of sensitivity and the presence of false positives. The EQA provides information on each laboratory's efficacy of RT-PCR techniques for dengue diagnosis and indicates for most laboratories an urgent need to improve sensitivity and specificity. Dengue viruses (DENV) are the most widespread arthropod-borne viruses which have shown an unexpected geographic expansion, as well as an increase in the number and severity of outbreaks in the last decades. In this context, the accurate diagnosis and reliable surveillance of dengue infections are essential. The laboratory diagnosis of dengue relies on the use of several methods detecting markers of DENV infection present in patient serum. Molecular diagnosis methods are usually rapid, sensitive, and simple when correctly standardized. Moreover, PCR-based diagnosis techniques are able to readily detect DENV during the acute phase of the disease and may assume an important role in dengue diagnosis and surveillance. Different reverse transcriptase PCR (RT-PCR) methods have been developed and are currently available and should be standardized in each laboratory to maintain high quality performance. In this work an External quality assessment (EQA) activity has been carried out to evaluate the accuracy and quality of laboratory data for the molecular diagnosis and surveillance of dengue, which involved worldwide dengue reference laboratories. In conclusion, RT-PCR techniques for dengue diagnosis applied by the participating laboratories demonstrated the need of further improvement in most laboratories.


  • Open Access

    International diagnostic accuracy study for the serological detection of chikungunya virus infection

    by M. Niedrig, H. Zeller, I. Schuffenecker, C. Drosten, P. Emmerich, L. Rumer, O. Donoso-Mantke


  • External quality assurance studies for the serological and PCR diagnostics of tick-borne encephalitis virus infections

    by Oliver Donoso Mantke, Stephan W. Aberle, Tatjana Avšič-Županc, Milan Labuda, Emöke Ferenczi, Baiba Rozentale, Matthias Niedrig


  • Open Access

    Analysis of the surveillance situation for viral encephalitis and meningitis in Europe

    by O Donoso Mantke, A Vaheri, H Ambrose, M Koopmans, F de Ory, H Zeller, K Beyrer, A Windorfer, M Niedrig, Representing The European Network F

    Infective processes in the brain, spinal cord and meninges are considered to be the main causes of encephalitis, myelitis and meningitis. However, most cases remain unexplained. The incidence of different viral aetiologies (zoonotic and non-zoonotic) is especially poorly estimated, due to the lack of a standard case definition and of agreed diagnostic algorithms, including harmonised diagnostic methods and sample collection. It is important to clarify the incidence of viral encephalitis/meningitis and to optimise the diagnosis of infectious neurological illness, particularly to ensure early recognition of outbreaks or emerging infections such as West Nile encephalitis. The European Network for Diagnostics of 'Imported' Viral Diseases (ENIVD) has analysed the present surveillance situation for viral encephalitis/meningitis in Europe. Here we give an overview of the existing epidemiological sources of information in European Union (EU) Member States, mapping the laboratory capacity and identifying key requirements for a possible future surveillance study at European level. The data presented will help design a harmonised/standardised Europe-wide surveillance study investigating patients with encephalitis and/or meningitis in order to obtain more information on the role of infections in these rarely analysed syndromes, both from a clinical and an epidemiological perspective. .


  • Open Access

    First international diagnostic accuracy study for the serological detection of West Nile virus infection

    by Matthias Niedrig, Oliver Donoso Mantke, Doris Altmann, Hervé Zeller

    The diagnosis of an acute or convalescent West Nile (WN) virus infection can be confirmed by various serological assays such as enzyme immunoassay (EIA), immunofluorescence assay (IFA), or neutralisation test (NT) which are conducted by a growing number of laboratories. However, as the degree of proficiency may vary between laboratories, quality control measures for laboratory diagnostics are essential. We have performed an external quality assurance (EQA) programme for the serological detection of WN virus infection to assess the diagnostic quality of laboratories. The participating laboratories received a proficiency panel of 10 coded lyophilised test samples comprising four antisera positive for WN antibodies as positive controls, three antisera positive for antibodies against other heterologous flaviviruses plus one multireactive unspecific serum as specificity controls, and two negative serum samples. Twenty-seven laboratories from 20 different countries in Europe, the Middle East, the Americas and Africa participated in this EQA programme. Applying the proficiency criteria of this study, only eight laboratories correctly analysed all samples with their respective EIA, IFA or NT methods. Eighteen laboratories correctly identified between 77.8 and 90% of the samples, and one laboratory identified only 70% correctly with a clear need to eliminate cross-reactivity with other antisera, particularly those elicited by yellow fever virus. Differentiation between the results for IgM and IgG was considered separately and revealed that IgM-antibodies were detected less frequently than IgG-antibodies (p < 0.001). However, the assay used was not a significant technical factor influencing laboratory performance. The EQA programme provides information on the quality of different serological assays used by the participating laboratories and indicates that most need to improve their assays, in particular to avoid cross-reactions with antibodies to heterologous flaviviruses.


  • Quality control assessment for the PCR diagnosis of tick-borne encephalitis virus infections

    by Oliver Donoso Mantke, Stephan W. Aberle, Tatjana Avšič-Županc, Milan Labuda, Matthias Niedrig